title: Level of cdk5 expression predicts the survival of relapsed multiple myeloma patients.
authors.forename: Zachary
authors.initials: Z
authors.lastname: Levacque
authors.forename: Jesusa L
authors.initials: JL
authors.lastname: Rosales
authors.forename: Ki-Young
authors.initials: KY
authors.lastname: Lee
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D001897:Boronic Acids / Q000627:therapeutic use; D000069286:Bortezomib; D051360:Cyclin-Dependent Kinase 5 / Q000378:metabolism*; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D053208:Kaplan-Meier Estimate; D009101:Multiple Myeloma / Q000188:drug therapy / Q000378:metabolism* / Q000401:mortality; D011719:Pyrazines / Q000627:therapeutic use; D012008:Recurrence
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib; D051360:Cyclin-Dependent Kinase 5